GenSci & IsoTis shareholders approve merger:
This article was originally published in Clinica
99.9% of Canadian firm GenSci's shareholders and 99.75% of IsoTis's have voted in favour of the merger of Swiss-Dutch IsoTis and GenSci OrthoBiologics, of Irvine, California. The group is hoping to double its combined revenues and reach profitability by 2005. In the six months to the end of June 2003, the two companies had combined sales of $11.8m and a net loss of $12.6m. The transaction is expected to close on October 27, and is dependent on the California Bankruptcy Court approving GenSci OrthoBiologics' emergence from Chapter 11 bankruptcy protection.
You may also be interested in...
US healthcare insurance provider Health Net failed to respect Amarin’s patent rights in the way it distributed Hikma’s generic version of Vascepa (icosapent ethyl), the originator contends in an expanded induced infringement suit.
Netherlands' Authority for Consumers and Markets has reprimanded a dietary supplements player for purchasing fake followers and likes on social media to exaggerate the popularity of its products. It is the first case of its kind in the country.
Developing biosimilar orphan drugs is fraught with challenges and needs buy-in from regulators, developers, patients and clinicians.